News

  • All
  • #TheTurningPointInCancerFight

Chronix Biomedical reports a positive interim analysis of its ongoing validation study of its Copy Number Instability (CNI)-based therapeutic monitoring test in pancreatic cancer. The study compares the accuracy of Chronix’s CNI-based test at predicting a clinical response, as early as after the first cycle of chemotherapy1 compared to CA19-9, a commonly used biomarker....

This is the third year that Chronix is presenting its study results at ASCO — this year’s results are from a blinded prospective study validating the use of a CNI Monitor blood test to predict the treatment outcome of patients undergoing immunotherapy...

The poster presentation is entitled Cell-free DNA for treatment monitoring and outcome predictor in head and neck cancer.

It presents data from a study that examined copy number instability (CNI) in circulating tumour DNA from 54 patients undergoing surgery for head and neck cancer and compared the Chronix CNI-based test as a predictor of time to progression with the current method based on the degree of tumour invasion of lymph nodes (pN status)....

World Cancer Day is a perfect opportunity to focus on your health state...